摘要
依曼替尼布是一种新型的 2 苯胺基嘧啶类酪氨酸激酶抑制药 ,用于α 干扰素治疗失败后的慢性髓样白血病 (CML)慢性期病人、加速期病人、急变期病人的治疗。
Imatinib is a novel tyrosine protein kinases inhibitor of the 2-phenylaminopyrimidine derivative. It is indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. The clinical studies shows that imatinib is very effective in hematologic response and major cytogenetic response in CML patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第9期567-569,共3页
Chinese Journal of New Drugs and Clinical Remedies